Clinical Trial Update: A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of nilotinib in pediatric patients with Philadelphia chromosome–positive CML or ALL; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2016-01-27